# Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

> **NCT05559879** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 37 (estimated)

## Conditions studied

- Gynecologic Cancer
- Carcinoma
- Uterine Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** Cabo + Dostarlimab

## Key facts

- **NCT ID:** NCT05559879
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-20
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559879, "Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05559879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*